H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

Researchers examine the impact of human movement on disease spread

Due to continual improvements in transportation technology, people travel more extensively than ever before. Although this strengthened connection between faraway countries comes with many benefits, it also poses a serious threat to disease control and prevention.

22 Sep 2020

Can amodiaquine short circuit this pandemic?

A recent study by the US researchers highlights the value of the human organ chip technology as a more robust and physiologically relevant platform for rapid drug repurposing, and suggest that amodiaquine may be used to prevent the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2020

Research compares T cell responses to SARS-CoV-2 and influenza

As the COVID-19 pandemic continues to grow, scientists are focusing on understanding how the host immune system responds to the virus in order to better shape public health responses and develop effective vaccines. A new study published on the preprint server medRxiv in September 2020 reports the T cell memory response to the SARS-CoV-2 spike protein, recombinant nucleocapsid protein, and other pooled peptides derived from convalescent patients.

3 Sep 2020

Dozens of U.S. hospitals poised to defy FDA’s directive on COVID plasma

Dozens of major hospitals across the U.S. are grappling with whether to ignore a federal decision allowing broader emergency use of blood plasma from recovered COVID patients to treat the disease in favor of dedicating their resources to a gold-standard clinical trial that could help settle the science for good.

3 Sep 2020

Health officials worry nation is not ready for COVID-19 vaccine

Millions of Americans are counting on a COVID-19 vaccine to curb the global pandemic and return life to normal.

2 Sep 2020

Silicon nitride shows potent SARS-CoV-2 neutralization capability

A new study published on the preprint server bioRxiv* in August 2020 shows that the man-made compound silicon nitride, which is used in medical implants and high mechanical performance engineering applications, is capable of inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at varying concentrations without causing cell cytotoxicity. This finding should be investigated to develop disinfectants to clear the virus from surfaces, preventing its spread.

1 Sep 2020

Pigs appear to be immune to SARS-CoV-2

Now, a team of researchers at Kansas State University aimed to determine if pigs are potential carriers of SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19).

18 Aug 2020

COVID-19 pandemic as severe as 1918 influenza pandemic

A recent study published in the journal JAMA Network Open reveals that the excess death toll observed during the initial period of coronavirus disease 2019 (COVID-19) pandemic in New York City is comparable to that observed during the peak of the H1N1 influenza pandemic in 1918.

14 Aug 2020

How have non-pharmaceutical interventions helped in COVID-19?

The COVID-19 pandemic shows no signs of abating, with outbreaks in many spots still occurring across the world. From the start, health organizations and governments were focused on implementing non-pharmaceutical interventions (NPIs) in the absence of any effective antivirals or vaccines.

9 Aug 2020

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.

7 Aug 2020

Humans promote diseases from the animal kingdom

The coronavirus pandemic, which has now infected nearly 19 million and killed more than 712,000 people, most likely originated from bats. Just like other coronavirus outbreaks in the past, a spill-over event or zoonosis caused the viruses to jump from animals to humans.

6 Aug 2020

Oxford Nanopore Technologies partners with UK Government to roll out LamPORE, a new generation of COVID-19 test

Oxford Nanopore today announces an agreement with the UK’s Department of Health and Social Care, to roll out its novel LamPORE test.

From Oxford Nanopore Technologies 3 Aug 2020

Meta-analysis shows 57% mortality reduction with convalescent plasma in COVID-19

Now, a new study published on the preprint server medRxiv in July 2020 reports that an older treatment modality, namely, the use of convalescent antibody-rich plasma, brings down the mortality rate in hospitalized COVID-19 patients by an astonishing 57%. This adds evidence for the use of convalescent plasma in the treatment of high-risk patients.

1 Aug 2020

Scientists develop human lung organoids to study SARS-CoV-2 infection

Now, a new study published on the preprint server bioRxiv in July 2020 reports the development of a human distal lung culture system that can be functionally tested. This will help not only to understand how this infection produces disease but also to test the proliferative capacity of the stem cells in this part of the body.

30 Jul 2020

Antimalarial drug shows in vitro activity against SARS-CoV-2 and flu viruses

Now, a new study published in the preprint server bioRxiv in July 2020 reports on the antiviral activity of two drugs found in an antimalarial drug currently in phase II trials in South Korea, called Pyramax.

30 Jul 2020

Fighting a pandemic is 500 times more expensive than the costs of preventive efforts

According to new research, the failure to protect tropical rain forests has cost trillions of dollars stemming from the coronavirus pandemic, which has wreaked economic havoc and caused historic levels of unemployment in the United States and around the world.

28 Jul 2020

Findings show promise for developing vaccines against multiple strains of flu, including SARS-CoV-2

A vaccine additive known as an adjuvant can enhance responses to a vaccine containing the exotic avian flu virus H5N1, so that both rookie and veteran elements of the immune response are strengthened, according to results from an Emory Vaccine Center study.

17 Jul 2020

Next showdown in Congress: Protecting workers vs. protecting employers in the pandemic

Congressional leaders are squaring off over the next pandemic relief bill in a debate over whom Congress should step up to protect: front-line workers seeking more safeguards from the ravages of COVID-19 or beleaguered employers seeking relief from lawsuits.

13 Jul 2020

New clinical trial to assess safety and efficacy of convalescent plasma to prevent COVID-19

There is only one approved, specific treatment for COVID-19, the illness caused by the novel coronavirus SARS-CoV-2, albeit with modest efficacy.

10 Jul 2020

Scientists recommend a decentralized biosurveillance system to protect from diseases

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans.